Chemoradiation after surgery for bile duct cancer
Part of Cancer clinical trials.
This trial tests whether combining chemotherapy with radiation after surgery can help prevent the return of intrahepatic cholangiocarcinoma, a type of bile duct cancer. It is for people whose surgery showed a narrow margin or cancer in nearby lymph nodes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You had surgery to remove your bile duct cancer, and doctors confirmed it was intrahepatic cholangiocarcinoma.
- After surgery, pathology showed the cancer was very close to the edge of what was removed (less than 1 cm) or that cancer was found in your lymph nodes.
- Your surgery completely removed the visible cancer (R0 or R1 resection).
- Your liver function is good, with a Child-Pugh score of A5 to B7.
- You are recovered enough from surgery that you can take care of yourself (ECOG score 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy drug (toripalimab) to standard chemotherapy before surgery can improve outcomes for people with intrahepatic cholangiocarcinoma that can be surgically removed. It's for patients who haven't had prior treatment for their cancer and are in good overall health.
This study tests additional treatment given after surgery to remove high-risk intrahepatic cholangiocarcinoma (a type of bile duct cancer). The goal is to reduce the chance the cancer comes back and improve survival in patients whose tumors had concerning features.
This trial tests a combination of chemotherapy directly to the liver, a targeted therapy pill, and an immunotherapy drug for people with advanced bile duct or gallbladder cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink or control the cancer.
This trial tests giving chemotherapy (cisplatin and gemcitabine) combined with an immunotherapy drug (rilvegostomig) before and after surgery for a type of bile duct cancer called intrahepatic cholangiocarcinoma that has a high risk of coming back. The goal is to see if this combination can reduce the chance of cancer returning.
This study tests whether combining chemotherapy and radiation therapy after surgery improves outcomes for patients with bile duct or gallbladder cancer. It's designed for patients whose surgery showed signs the cancer might come back.
This trial tests whether combining immunotherapy with chemotherapy and radiation after surgery can help prevent bile duct cancer from coming back in people who have a high risk of recurrence.
Hear when a new Intrahepatic Cholangiocarcinoma (Icc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.